J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Johnson & Johnson is partnering with the Japanese company Kaken on a STAT6 program. J&J will get the rights to KP-723, an oral STAT6 inhibitor still ...